Stocks › ALNY
ALNYLAM PHARMACEUTICALS, INC.
ALNY·Nasdaq·
United States·USD
United States·USD$223.94
+4.05 (+1.84%)
Close · Oct 6, 2026 · Close Prices from Tiingo.com
ALNY
ALNYLAM PHARMACEUTICALS, INC. · Nasdaq
Nasdaq 100S&P 500
Filings
Default90D1Y5YALL
ALNYS&P 500 (rebased)
Congress BuyCongress SellInsider BuyInsider SellForm 1448-K ResultsLobbying
Loading price history…
Daily closes, adjusted for splits and dividends · Close Prices from Tiingo.comHover a marker, every one is a filing · move across the line for the crosshair
Congressional Trades
Recent trades of ALNY by members of U.S. Congress · 20 on record · 1 in the last 12 months
Whale Activity
Position changes in ALNY reported for 2026-06-30 by 15 tracked institutional filers
- Increased5
- New0
- Held0
- Decreased4
- Closed0
- No prior filing6
| Filer | Shares | Value | Change |
|---|---|---|---|
| BlackRock, Inc. | 10.9M | $3.28B | increased |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 6.5M | $1.97B | increased |
| VANGUARD CAPITAL MANAGEMENT LLC | 6.0M | $1.82B | increased |
| TWO SIGMA INVESTMENTS, LP | 1.9M | $564.7M | decreased |
| AMERICAN CENTURY COMPANIES INC | 1.9M | $558.1M | — |
| D. E. Shaw & Co., Inc. | 1.1M | $332.4M | increased |
| LOS ANGELES CAPITAL MANAGEMENT LLC | 729.6K | $219.6M | — |
| LOOMIS SAYLES & CO L P | 580.2K | $174.7M | — |
| MILLENNIUM MANAGEMENT LLC | 316.0K | $95.1M | decreased |
| CITADEL ADVISORS LLC | 191.0K | $57.5M | increased |
| Bridgewater Associates, LP | 99.6K | $30.0M | decreased |
| BOUSSARD & GAVAUDAN GESTION SAS | 24.8K | $29.7M | — |
KeyVex tracks a curated set of large 13F filers plus the largest positions in recent filings, so this is a sample of institutional activity, not the whole market.
Insider Trading
Net shares bought (+) or sold (−) on the open market by ALNY insiders, by quarter · Form 4
Recent Insider Transactions
2,441 transactions on record · newest first
| Insider | Type | Shares | Price | Value | Date | |
|---|---|---|---|---|---|---|
| SUPRAN BRYANEVP, CLO and Secretary | Sale | −1,758 | $226.88 | $399K | Oct 2, 2026 | Form 4 ↗ |
| PYOTT DAVID E IDirector | Sale | −17 | $302.65 | $5K | Jun 1, 2026 | Form 4 ↗ |
| PYOTT DAVID E IDirector | Sale | −495 | $300.72 | $149K | Jun 1, 2026 | Form 4 ↗ |
| PYOTT DAVID E IDirector | Sale | −1,222 | $299.87 | $366K | Jun 1, 2026 | Form 4 ↗ |
| PYOTT DAVID E IDirector | Sale | −1,175 | $298.91 | $351K | Jun 1, 2026 | Form 4 ↗ |
| PYOTT DAVID E IDirector | Sale | −921 | $297.71 | $274K | Jun 1, 2026 | Form 4 ↗ |
| PYOTT DAVID E IDirector | Option exercise | +3,830 | $0.00 | $0 | Jun 1, 2026 | Form 4 ↗ |
| Sigal Charles ElliottDirector | Grant / award | +671 | $0.00 | $0 | May 20, 2026 | Form 4 ↗ |
| SCHULMAN AMY WDirector | Grant / award | +838 | $0.00 | $0 | May 20, 2026 | Form 4 ↗ |
| Reitan Colleen FDirector | Grant / award | +671 | $0.00 | $0 | May 20, 2026 | Form 4 ↗ |
| PYOTT DAVID E IDirector | Grant / award | +671 | $0.00 | $0 | May 20, 2026 | Form 4 ↗ |
| KELLOGG PETER NDirector | Grant / award | +671 | $0.00 | $0 | May 20, 2026 | Form 4 ↗ |
| HAMBURG MARGARET ADirector | Grant / award | +671 | $0.00 | $0 | May 20, 2026 | Form 4 ↗ |
| BRANDICOURT OLIVIERDirector | Grant / award | +671 | $0.00 | $0 | May 20, 2026 | Form 4 ↗ |
| Ausiello Dennis ADirector | Grant / award | +671 | $0.00 | $0 | May 20, 2026 | Form 4 ↗ |
| Arbuckle Stuart ADirector | Grant / award | +671 | $0.00 | $0 | May 20, 2026 | Form 4 ↗ |
| SCHULMAN AMY WDirector | Option exercise | +11.3K | $70.20 | $790K | May 13, 2026 | Form 4 ↗ |
| McLaughlin MelissaChief Human Resources Officer | Sale | −199 | $333.94 | $66K | Apr 6, 2026 | Form 4 ↗ |
| McLaughlin MelissaChief Human Resources Officer | Sale | −293 | $331.89 | $97K | Apr 6, 2026 | Form 4 ↗ |
| McLaughlin MelissaChief Human Resources Officer | Sale | −829 | $330.46 | $274K | Apr 6, 2026 | Form 4 ↗ |
Fund Holders
Mutual funds and ETFs holding ALNY · SEC Form N-PORT
| Fund | Shares | Value | % of fund | As of |
|---|---|---|---|---|
| Growth Fund of America | 7.7M | $2.32B | 0.64% | May 31, 2026 |
| VANGUARD TOTAL STOCK MARKET INDEX FUND VANGUARD INDEX FUNDS | 4.2M | $1.28B | 0.06% | Jun 30, 2026 |
| AMCAP Fund | 4.1M | $1.24B | 1.27% | May 31, 2026 |
| VANGUARD MID-CAP INDEX FUND VANGUARD INDEX FUNDS | 2.9M | $870.9M | 0.39% | Jun 30, 2026 |
| Invesco QQQ Trust, Series 1 | 2.8M | $853.1M | 0.17% | Jun 30, 2026 |
| T. Rowe Price Capital Appreciation Fund T. ROWE PRICE CAPITAL APPRECIATION FUND, INC. | 2.0M | $612.5M | 0.87% | Jun 30, 2026 |
| VANGUARD GROWTH INDEX FUND VANGUARD INDEX FUNDS | 1.6M | $488.9M | 0.13% | Jun 30, 2026 |
| Investment Co of America | 1.6M | $485.5M | 0.26% | Jun 30, 2026 |
| VANGUARD EXTENDED MARKET INDEX FUND VANGUARD INDEX FUNDS | 1.5M | $460.8M | 0.47% | Jun 30, 2026 |
| Fidelity OTC Portfolio Fidelity Securities Fund | 2.1M | $440.0M | 1.02% | Jul 31, 2026 |
Mutual funds and ETFs whose N-PORT filings list ALNY's shares (CUSIP 02043Q107), each fund at its latest report since Mar 7, 2026, largest positions first. Bonds, options and short positions are left out.
Activist & Passive Stakes
Schedule 13D / 13G beneficial-ownership filings
- Capital World InvestorsSCHEDULE 13G/A · passive (13G) · 10.9M shares8.2%
May 14, 2026 · ↗ - Capital Research Global InvestorsSCHEDULE 13G/A · passive (13G) · 9.5M shares7.1%
May 14, 2026 · ↗ - Abigail P. JohnsonSCHEDULE 13G/A · passive (13G) · 14.6M shares11.0%
May 6, 2026 · ↗ - FMR LLCSCHEDULE 13G/A · passive (13G) · 14.6M shares11.0%
May 6, 2026 · ↗
Corporate Lobbying
Estimated quarterly lobbying spending reported under the LDA, filings naming alnylam pharmaceuticals as client
- ALNYLAM PHARMACEUTICALS, INC.ALNYLAM PHARMACEUTICALS, INC. · 2026 Q2 · PHA, MMM, TRD$450K
Filing ↗ - SPLITOAK STRATEGIES LLCALNYLAM PHARMACEUTICALS, INC. · 2026 Q2 · MMM$60K
Filing ↗ - TODD STRATEGY GROUPALNYLAM PHARMACEUTICALS, INC. · 2026 Q2 · MMM$60K
Filing ↗ - TIBER CREEK GROUPALNYLAM PHARMACEUTICALS, INC. · 2026 Q2 · MMM$60K
Filing ↗ - CAPITOL COUNSEL LLCALNYLAM PHARMACEUTICALS, INC. · 2026 Q2 · MED$30K
Filing ↗
Government Contracts
Federal awards to ALNYLAM PHARMACEUTICALS, INC. · USAspending
No federal contract awards found for ALNYLAM PHARMACEUTICALS, INC..
U.S. Patents
Recent USPTO applications naming ALNYLAM PHARMACEUTICALS, INC.
No USPTO patent applications found for ALNYLAM PHARMACEUTICALS, INC..
Annual Financials
From ALNY's 10-K filings · XBRL
No annual XBRL figures on record for ALNY. KeyVex's fundamentals cover about 130 large companies so far.
Stock Splits
Every split and reverse split in the price history
No stock splits in ALNY's price history.
About ALNYLAM PHARMACEUTICALS, INC.
From SEC EDGAR company records
Industry (SIC 2834)Pharmaceutical Preparations
SectorHealthcare
HeadquartersCAMBRIDGE, MA
SEC CIK0001178670 ↗
Former namesALNYLAM PHARMACEUTICALS INC